HaemoAdsorption Nach Reanimation An ECMO (HANRAE)

This study evaluates the use of an additional hemoadsorption device in adult patients undergoing veno-arterial extracorporal membrane oxygenation (ECMO) following cardiac arrest and cardiopulmonary resuscitation in respect to its effects on post resuscitation inflammatory syndrome.

At implantation of the ECMO the participants are going to be randomized into a treatment and a control group. The first will be outfitted with a polymer-based adsorption device implemented in the extracorporal circulation established by ECMO for 48h, the control group is going to be treated by ECMO and standard intensive care alone. To detect any significant differences in terms of inflammatory response and patient outcome the investigators will regularly determine the blood levels of certain cytokines in fixed intervalls. In addition, the investigators are going to compare secondary clinical outcome parameters like organ disfunction and 30d mortality.

Study Overview

• Status: Unknown
• Conditions: Inflammation; Cardiac Arrest; Resuscitation; Multi-Organ Disorder
• Intervention / Treatment: Device: Hemoadsorption

Detailed Description

Even after successful return of spontaneus circulation (ROSC), patients suffering a cardiac arrest with subsequent cardipulmonary resuscitation (CPR) are still facing a significant morbidity and mortality in the post-resuscitation phase. They are nowadays often subjected to extracorporal membrane oxygenation (ECMO), supplementing or even replacing cardiac and/or pulmonary function for a certain period in order to reduce the workload for these critical organs. However, as well as the initial ischemia/reperfusion damage, subsequent procedures create significant stress to the patients organism, causing severe inflammation and contributing to post-resuscitation single or multiple organ disfunction and/or failure.

Continously eliminating relevant mediators of inflammation by adsorption to a polymer-based material in extracorporal circulation has been shown to influence the course of this inflammatory syndrome in patients with severe infection and sepsis. Any relevant clinical studies evaluating the use of such a device in post-resuscitation care are still lacking, yet.

Therefore, in this study the investigators are going to test the hypothesis that such a device is capable of significantly altering the cytokine levels during and even shortly after a 48h treatment period in addition to the standard ECMO therapy all patients are going to receive. As a secondary outlook, the investigators are going to compare the clinical outcome of the patients in terms of major organ disfunction and overall 30d mortality.

At the time extracoporal circulation is established during or after CPR, all participants (n=40) are enrolled and randomized into a treatment and a control group. The extracorporal circulation over the ECMO device is then outfitted with a certified in line adsorption cartridge for the treatment group. Due to technical reasons, this cartridge has to be exchanged for another identical module after 24h of continuous treatment. Adsorption therapy is terminated after 48h. The control group is subjected to ECMO without any additional modules. Both groups are receiving standard intensive care during the course of the study. All diagnostic and therapeutic decisions with the exemption of those directly concerning the hemoadsorption and sampling protocol are at sole discretion of the clinical staff.

For both groups, blood samples are taken at time points 0,6,12,24,36,48,72h after establishment of ECMO or time of death, respectively. Relevant parameters are then determined in different diagnostic and research laboratories with/without sample preprocessing by the study personal in accordance with preanalytic requirements. All relevant clinical data is extracted from the digital patient data management system (PDMS).

• Study Type: Interventional
• Enrollment (Anticipated): 40
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Germany
  • Hamburg, Germany, 20246
    • Recruiting
    • University Hospital Hamburg-Eppendorf
    • Contact: Jens Kubitz, Prof. Dr.; Phone Number: +49 (0) 40 7410 - 52415; Email: j.kubitz@uke.de
    • Contact: Eike Pfefferkorn, Dr.; Email: e.pfefferkorn@uke.de

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

All patients receiving a veno-arterial ECMO after cardiac arrest at the study site are eligible for the study. Thus, the criteria are defined by the SOP "ECMO bei Reanimation" of the University Heart Center Hamburg:

Inclusion Criteria:

• observed cardiac arrest with initial hyperdynamic rhythm and sufficient primary resuscitation

Exclusion Criteria (absolute):

• existing "do-not-resuscitate"-order from the patient/a priori palliative situation
• severe trauma
• severe acute bleeding due to any cause
• confirmed or highly likely relevant and severe persistent neurologic impairment
• severe limiting comorbidities with independent and relevant reduction of life expectancy (e.g. malignoma, preexistent heart failure syndrome, obstructive/restrictive lung disease, hepatic cirrhosis)

Exclusion Criteria (relative, at the discretion of the responsible provider):

• severe initial lacacidosis
• prolongued mechanical resuscitation (>30min)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Treatment; Inclusion of an extracorporal in line adsorbing cartridge for 48h (with a cartridge exchange at 24h) post establishing ECMO in addition to standard post resuscitation intensive care	Device: Hemoadsorption; see arm description
No Intervention: Control; ECMO and standard post resuscitation intensive care without any additional module in extracorporal circulation

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
IL-6 at hour 6	Blood levels of interleukine 6 will be compared between intervention and control group	6 hours post establishment of extracorporal membrane oxygenation (ECMO)
IL-6 at hour 12	Blood levels of interleukine 6 will be compared between intervention and control group	12 hours post establishment of extracorporal membrane oxygenation (ECMO)
IL-6 at hour 24	Blood levels of interleukine 6 will be compared between intervention and control group	24 hours post establishment of extracorporal membrane oxygenation (ECMO)
IL-6 at hour 48	Blood levels of interleukine 6 will be compared between intervention and control group	48 hours post establishment of extracorporal membrane oxygenation (ECMO)
IL-6 at hour 72	Blood levels of interleukine 6 will be compared between intervention and control group	72 hours post establishment of extracorporal membrane oxygenation (ECMO)
TNF-a at hour 6	Blood levels of human tumor necrosis factor alpha will be compared between intervention and control group	6 hours post establishment of extracorporal membrane oxygenation (ECMO)
TNF-a at hour 12	Blood levels of human tumor necrosis factor alpha will be compared between intervention and control group	12 hours post establishment of extracorporal membrane oxygenation (ECMO)
TNF-a at hour 24	Blood levels of human tumor necrosis factor alpha will be compared between intervention and control group	24 hours post establishment of extracorporal membrane oxygenation (ECMO)
TNF-a at hour 48	Blood levels of human tumor necrosis factor alpha will be compared between intervention and control group	48 hours post establishment of extracorporal membrane oxygenation (ECMO)
TNF-a at hour 72	Blood levels of human tumor necrosis factor alpha will be compared between intervention and control group	72 hours post establishment of extracorporal membrane oxygenation (ECMO)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
S1P	Blood levels of sphingosine-1-phosphate will be compared between intervention and control group.	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
PCT	The serum levels of procalcitonine will be compared between intervention and control group.	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
CRP	The plasma levels of C-related peptide will be compared between intervention and control group.	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Leukocytes	The number of leukocytes in simple blood count will be compared between intervention and control group.	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
BNP	The serum levels of n-terminal pro brain natriuretic peptide will be compared between intervention and control group.	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Mean arterial pressure (MAP)	The mean arterial pressure as calculated automatically from the invasively measured arterial pressure curve will be compared between intervention and control group.	Continuosly from enrollment to 72h post.
Heart rate (HR)	The continuously monitored heart rate will be compared between intervention and control group.	Continuosly from enrollment to 72h post.
Central venous pressure (CVP)	The continuously and invasively measured mean central venous pressure will be compared between intervention and control group, if available.	Continuosly from enrollment to 72h post.
haemodynamically relevant medication	The continuous intake of the following drugs as chosen by discretion of the clinical staff is extracted from digital PDMS: Norepinephrine, Epinephrine, Dobutamin, inodilatators (Milrinon, Enoximon, Levosimendan)	Continuosly from enrollment to 72h post.
Trop	The serum levels of troponine T will be compared between intervention and control group	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
CK	The Plasma levels of creatinkinase will be compared between intervention and control group.	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Myoglobine	The Serum levels of myoglobine will be compared between intervention and control group.	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Hemoglobine	The total blood concentration of hemoglobine will be compared between intervention and control group.	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Haptoglobine	The serum levels of haptoglobine will be compared between intervention and control group.	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
paO2	The arterial partial pressure of oxygen as measured by point-of-care blood gas analysis is going to be compared between intervention and control group	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
paCO2	The arterial partial pressure of carbon dioxide as measured by point-of-care blood gas analysis is going to be compared between intervention and control group.	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
SaO2	The saturation of hemoglobine with oxygen in an arterial blood sample as measured by point-of-care blood gas analysis is going to be compared between intervention and control group.	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
SvO2	The saturation of hemoglobine with oxygen in a central venous blood sample as measured by point-of-care blood gas analysis is going to be compared between intervention and control group.	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Horowitz index	The Horowitz index, calculated as paO2/FiO2 is going to be compared between intervention and control group.	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
pH	The pH of an arterial blood sample is going to be compared between intervention and control group.	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
HCO3	The levels of bicarbonate of an arterial blood sample are going to be compared between intervention and control group.	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
BE	The base excess of an arterial blood sample is going to be compared between intervention and control group.	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
N	The blood levels of sodium are going to be compared between intervention and control group.	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
K	The blood levels of potassium are going to be compared between intervention and control group.	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
C	The blood levels of chloride are going to be compared between intervention and control group.	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Lactate	The blood levels of lactate are going to be compared between intervention and control group.	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Mode of Ventilation	The mode of mechanical ventilation is going to be compared between intervention and control group	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
FiO2	The inspiratory oxygen fraction at mechanical ventilation is going to be compared between intervention and control group	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Peak inspiratory pressure (pmax)	The peak inspiratory pressure at mechanical ventilation is going to be compared between intervention and control group	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
PEEP	The positive end exspiratory pressure at mechanical ventilation is going to be compared between intervention and control group	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Ventilation frequency	The frequency of mechanical ventilation (cycles/min) is going to be compared between intervention and control group.	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Tidal volume	The tidal volume achieved by mechanical ventilation is going to be compared between intervention and control group.	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Total minute ventilation	The total minute ventilation as measured by the ventilation unit is going to be compared between intervention and control group.	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Complicance	The airway compliance (c) as calculated from ventilator driving pressure(dp=pmax-PEEP) and tidal volume (V): c=V/dp is going to be compared between intervention and control group.	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
ASAT	The plasma levels of asparic acid aminotransferase will be compared between intervention and treatment group.	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
ALAT	The plasma levels of alanin aminotransferase will be compared between intervention and treatment group.	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
INR	The thrombin time as standardized international normal ratio will be compared between intervention and treatment group.	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
apTT	The activated partial thromboplastin time will be compared between intervention and treatment group.	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Crea	The plasma creatinine concentration will be compared between intervention and treatment group.	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
eGFR	The glomerulary filtration rate, estimated from serum creatinine by the CKP-EPI formula will be compared between intervention and treatment group.	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Volume status	For a clinical estimation of the renal function, the following parameters are extracted from the digital PDMS: Fluid intake, diuresis, additional loss of body fluids (e.g. gastral reflux, vomitting, extraction by kidney replacement therapy)	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
NSE	The serum levels of neuron specific enolase will be compared between intervention and treatment group.	at hours 0,6,12,24,48,72 post establishment of extracorporal membrane oxygenation (ECMO)
Mortality	Mortality within 30 days after enrollment due to any cause will be determined, if follow up is technically feasible	30 days post enrollment

Collaborators and Investigators

• Sponsor: Universitätsklinikum Hamburg-Eppendorf
• Collaborators: CytoSorbents Corporation and CytoSorbents Medical Inc.
• Investigators: Principal Investigator: Jens Kubitz, Prof. Dr., Universitätsklinikum Hamburg-Eppendorf

Publications and helpful links

General Publications

• Adrie C, Laurent I, Monchi M, Cariou A, Dhainaou JF, Spaulding C. Postresuscitation disease after cardiac arrest: a sepsis-like syndrome? Curr Opin Crit Care. 2004 Jun;10(3):208-12. doi: 10.1097/01.ccx.0000126090.06275.fe.
• Kellum JA, Song M, Venkataraman R. Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-kappaB DNA binding, and improves short-term survival in lethal endotoxemia. Crit Care Med. 2004 Mar;32(3):801-5. doi: 10.1097/01.ccm.0000114997.39857.69.
• Peng ZY, Carter MJ, Kellum JA. Effects of hemoadsorption on cytokine removal and short-term survival in septic rats. Crit Care Med. 2008 May;36(5):1573-7. doi: 10.1097/CCM.0b013e318170b9a7.
• Bruenger F, Kizner L, Weile J, Morshuis M, Gummert JF. First successful combination of ECMO with cytokine removal therapy in cardiogenic septic shock: a case report. Int J Artif Organs. 2015 Feb;38(2):113-6. doi: 10.5301/ijao.5000382. Epub 2015 Feb 3.
• Bernardi MH, Rinoesl H, Dragosits K, Ristl R, Hoffelner F, Opfermann P, Lamm C, Preissing F, Wiedemann D, Hiesmayr MJ, Spittler A. Effect of hemoadsorption during cardiopulmonary bypass surgery - a blinded, randomized, controlled pilot study using a novel adsorbent. Crit Care. 2016 Apr 9;20:96. doi: 10.1186/s13054-016-1270-0.
• Tomescu DR, Olimpia Dima S, Ungureanu D, Popescu M, Tulbure D, Popescu I. First report of cytokine removal using CytoSorb(R) in severe noninfectious inflammatory syndrome after liver transplantation. Int J Artif Organs. 2016 May 16;39(3):136-40. doi: 10.5301/ijao.5000489. Epub 2016 Apr 14.

Study record dates

Study Major Dates

• Study Start (Anticipated): October 1, 2018
• Primary Completion (Anticipated): May 1, 2019
• Study Completion (Anticipated): September 1, 2019

Study Registration Dates

• First Submitted: May 3, 2018
• First Submitted That Met QC Criteria: August 10, 2018
• First Posted (Actual): August 16, 2018

Study Record Updates

• Last Update Posted (Actual): August 16, 2018
• Last Update Submitted That Met QC Criteria: August 10, 2018
• Last Verified: August 1, 2018

More Information

Terms related to this study

• Keywords: hemoadsorption; extracorporal circulation; post resuscitation syndrome
• Additional Relevant MeSH Terms: Pathologic Processes; Inflammation
• Other Study ID Numbers: UKEHANRAE

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes